PARTIAL SECTION 71 ACCEPTED
on 27 Jun 2024
Last Applicant/ Owned by
Meditrina
Cambridge
GB
CB223AT
Serial Number
79179556 filed on 17th Dec 2014
Registration Number
5158366 registered on 14th Mar 2017
Correspondent Address
Rebecca Liebowitz
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
HUMABODY
[ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
[ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, drug discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design ]
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; veterinary preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; antibody fragments being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases] ; antibody therapeutics in the nature of therapeutic agents for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; medical diagnostic reagents and veterinary diagnostic reagents in the nature of antibodies and antibody fragments; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] and or use in the manufacture of therapeutic products
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
chemicals used in industry and science; [ chemical test kits for in vitro testing for laboratory research purposes; ] biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments for in vitro scientific and laboratory research use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [040]
Treatment & Processing of Materials Services
[ Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments ]
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79179556
Mark Type
No Service Mark
Attorney Docket Number
No 31229-422717
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 08th Nov 2024 | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED |
| 27th Jun 2024 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED |
| 27th Jun 2024 | REGISTERED - PARTIAL SEC 71 ACCEPTED |
| 07th May 2024 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| 27th Oct 2023 | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| 13th Sep 2023 | TEAS SECTION 71 RECEIVED |
| 19th Aug 2023 | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED |
| 14th Mar 2022 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| 07th Dec 2017 | NEW REPRESENTATIVE AT IB RECEIVED |
| 14th Jul 2017 | FINAL DECISION TRANSACTION PROCESSED BY IB |